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Acute myocardial infarctionAbstract Background: Acute myocardial infarction (AMI) is an acute stress state in which plasma
copeptin rises. The combination of copeptin and troponin has been suggested to improve the diag-
nostic performance of acute MI in chest pain patients at time of presentation in the emergency
department.
Objective: To investigate the correlation of plasma copeptin levels for early exclusion of acute
myocardial infarction in combination with troponin-I.
Methods: This study was conducted in Cairo University hospitals on 40 patients presented to the
critical care department with chest pain within 6 h of pain onset as a primary symptom of acute
coronary syndrome. Baseline demographic characteristics and clinical data were collected prospec-
tively. Plasma copeptin levels and cTnI were measured by ELISA technique. The primary outcome
was diagnosis of AMI.
Results: A negative copeptin and cTnI at baseline ruled out AMI with a negative predictive
value of 100%. AMIs not detected by the initial cTnI alone were picked up with copeptin
>15.6 pg/ml in ﬁrst 6 h from onset of chest pain which was conﬁrmed by repeated troponin within
12 h from onset of chest pain.
Conclusion: Combined measurements of troponin and copeptin aid in early and safe rule-out of
AMI.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).a1961@
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Initial evaluation for acute myocardial infarction (AMI) relies
on 12-lead electrocardiography recording and biomarker anal-
ysis, in complement to clinical assessment [1]. Cardiac troponin
(cTn) T and I are the standard markers for myocardial necro-
sis, and an elevation in cTn is considered as part of the univer-
sal deﬁnition of myocardial infarction [2].
The adequate ruling out of acute coronary syndrome (ACS)
in patients with chest pain is crucial, as the erroneous discharge
of a patient with ACS is associated with a high risk of cardiac
events [3]. Copeptin, a relatively novel biomarker, is the c-
terminal of the vasopressin precursor hormone and is co-
secreted with the hormone [4].
Normal plasma level of copeptin in healthy volunteers
ranges between 1.0 and 14 pmol/L with a median value below
5.0 pmol/L. Its level in men is slightly higher than in women
with a difference in median value by 1.0 pmol/L [5].
There are no data supporting any ﬁxed correlations
between copeptin levels and common risk factors apart from
dyslipidemia; however, the data on dyslipidemia are conﬂicting
[6–8].
Copeptin has a longer half-life than vasopressin; it is easier
to detect and directly reﬂects vasopressin release. Copeptin,
and thereby vasopressin, are released by endogenous stress
and increase immediately after the onset of chest pain [9].
The combination of a marker of endogenous stress and a mar-
ker of cell necrosis can improve the diagnostic performance in
patients with chest pain at the time of presentation in the emer-
gency department [10].
2. Patients and methods
This observational prospective study was conducted in Cairo
University hospitals on 40 patients who presented to the criti-
cal care department with chest pain as a primary symptom of
possible acute coronary syndrome.
2.1. Inclusion criteria
Any adult patient with an ageP 18 years who presented with
the following symptoms:
1. Typical chest pain (i.e., substernal compressing chest pain
or discomfort caused by exertion or emotional stress and
relieved by rest and/or nitroglycerin) associated with or
without ECG changes.
2. Patients should present within 6 h from onset of chest pain.
2.2. Exclusion criteria
1. Age < 18 years.
2. Patients with symptoms that were not clearly the result of
ACS [i.e., atypical chest pain].
3. Sepsis.
4. Shock.
5. End-stage liver and renal diseases.
6. Recent cerebrovascular stroke.
7. History of peripheral vascular disease.2.3. All patients included in the study were subjected to the
following
1. Full medical history, full clinical examination, ECG on
admission and every 6 h for the next 24 h and as required,
and then daily ECG till discharge.
2. All patients received medical treatment for acute coronary
syndrome according to the AHA/ACC 2014 guidelines.
3. Routine laboratory investigations.
4. Speciﬁc laboratory investigations:
1.1. Creatine Phosphokinase (CPK) and Myocardial band
Creatine Kinase (CKMB).
1.2. Troponin-I within 6 h and 12 h from onset of chest
pain by ELISA technique of ACCU-Bind ELISA
Microwells (Troponin-I test system product code: 3-
825–300. With adult (normal) 6 1.3 ng/ml according
to the kit).
1.3. Plasma Copeptin was done to all patients within 6 h
from onset of chest pain by ELISA technique (Hu-
man Copeptin, CPP ELISA Kit Catalog No: E0365 h
with adult (normal) 6 15.6 pg/ml according to the
kit). Keller et al. evaluated different potential cutoff
values for copeptin in a large reference population
(n= 1386), where the 99th, 97th, and 95th percentile
cutoff values were 18.9 pmol/l, 13 pmol/l, and 9.8 p-
mol/l, respectively. Most clinical studies used a cop-
eptin cutoff of 14 pmol/l. This cutoff was driven by
the ﬁrst copeptin assay available and is still used in
most studies [11].2.4. Statistical methodology
Analysis of data was done by IBM computer using SPSS (sta-
tistical program for social science version [12]).
 Mean and SD were calculated for quantitative variables
while number and percentage for were used to denote qual-
itative variables.
 Chi-square test was used to compare qualitative variables,
and unpaired t-test was used to compare quantitative vari-
ables, in parametric data (SD < 50% mean).
 Mann-Whitney-Wilcoxon U test was used for non-
parametric data.
 ROC curve (receiver operator characteristic) was used to
ﬁnd out the best cut-off value and validity of certain
variable.
 Sensitivity and speciﬁcity tests were also used.
3. Results
3.1. Descriptive data
3.1.1. Demographic data
The age of the studied group ranged from 48 to 65 years with a
mean of 56 ± 4.6 years. Thirty-four patients (85%) were males
and 6 patients (15%) were females (Table 1).
Table 1 Descriptive data of the study group.
Variable Number Percentage Mean ± SD
Age 40 56 ± 4.6
Male 34 85
Female 6 15
Smoking 18 45
FH of IHD 8 20
Dyslipidemia 25 62.5
DM 23 57.5
Hypertension 33 82.5
Previous CAD 24 60
ECG changes:
No changes 3 7.5
ST depression 21 52.5
ST elevation 15 37.5
LBBB 1 2.5
Copeptin 6 h:
P15.6 pg/ml 32 80 53.46 ± 93.77
<15.6 pg/ml 8 20 8.67 ± 5.56
Troponin 6 h:
P1.3 ng/ml 7 17.5 13.9 ± 19.13
<1.3 ng/ml 33 82.5 0.3 ± 0.032
Troponin 12 h:
P1.3 ng/ml 32 80 11.82 ± 14.37
<1.3 ng/ml 8 20 0.68 ± 0.37
FH, family history; DM, diabetes mellitus; CAD, coronary artery
disease; ECG, electrocardiography; LBBB, left bundle branch
block.
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All patients had at least one risk factor. The most frequent risk
factor was hypertension (82.5%) followed by dyslipidemia
(62.5%), previous CAD (60%), diabetes mellitus (57.5%),
smoking (45%), and +ve family history (20%) (Table 1).
3.1.3. ECG findings
The most frequent ECG changes were ST segment depression
in 21 patients (52.5%), ST segment elevation in 15 patients
(37.5%), and LBBB in only one patient (2.5%). No ECG
changes were elicited in 3 patients (7.5%) (Table 1).
3.1.4. Laboratory findings: Troponin & copeptin in the studied
group
3.1.4.1. During the first 6 h. Serum Troponin-I in the ﬁrst 6 h
was high (P1.3 ng/ml) in 7 patients (17.5%) with a mean
± SD of 13.9 ± 19.13 and negative in 33 patients (82.5%).
Serum copeptin level was high (P15.6 pg/ml) in 32 patients
(80%) with a mean ± SD of 53.46 ± 93.77 and negative in 8
patients (20%) (Table 1).
3.1.4.2. After 12 h from admission. Serum troponin after 12 h
from admission was high (P1.3 ng/ml) in 32 patients (80%)
with a mean ± SD of 11.82 ± 14.37, and negative in 8
patients (20%) (Table 1).
3.2. Comparative data
3.3.1. Copeptin with risk factors and ECG changes
Our study showed a signiﬁcant relation between high copeptin
and dyslipidemic patients with a P-value of 0.041 and an
insigniﬁcant relation with other risk factors. There was no sig-
niﬁcant relation between ECG and copeptin levels in the study
group (Table 1).
3.3.2. Copeptin with troponin in 6 h
Our study showed an insigniﬁcant correlation between tro-
ponin and copeptin in the ﬁrst 6 h from the onset of chest pain
(Table 2).
The sensitivity of copeptin with troponin measured in 6 h is
100% while the speciﬁcity is 24.2%. Positive predictive value is
21.2%, and the negative predictive value is 100% (Table 3).
3.3.3. Copeptin with troponin in 12 h
Our study showed a strong +ve correlation between serum
levels of copeptin within 6 h from onset of chest pain and tro-
ponin after 12 h (Table 4).
The sensitivity of copeptin with troponin measured in 12 h
is 96.8% and the speciﬁcity is 87.5%. The positive predictive
value of copeptin and troponin measured in 12 h is 96.8%
while the negative predictive value is 87.5% (Table 5).
3.3.4. ROC curve of copeptin as a predictor of myocardial
infarction
The receiver operator characteristic (ROC) curve was calcu-
lated for copeptin as a predictor for myocardial infarction
(MI). The area under the curve (AUC) for copeptin to predict
MI was 98% with conﬁdence interval (CI) 0.94/1.0. The opti-
mal cut-off value of copeptin to predict MI was 21.1 pg/mlwith a sensitivity of 100% and speciﬁcity of 87.1%, and the
overall accuracy was 93.5% with P value 0.001 (Fig. 1 and
Table 6).
4. Discussion
Copeptin is a novel neuroendocrine peptide that was recently
introduced to the ﬁeld of acute medicine biomarkers. In acute
stress condition, copeptin rises and reﬂects stress level exactly
like arginine vasopressin (AVP), which was largely known as
a mediator of non-speciﬁc stress conditions beside its promi-
nent role in water homeostasis.
In recent years, many studies reported that when copeptin
is combined with cardiac troponins in diagnosis of patients
presenting with acute chest pain in early hours, it accelerates
early rule in of AMI and rule out of non-MI patients [12].
In CHOPIN trial, one of the largest multicenter studies on
consecutive patients with chest pain, only approximately 8%
had a ﬁnal gold standard diagnosis of AMI (STEMI and
NSTEMI), whereas >60% had a non-cardiac origin of their
symptoms. The results showed that the addition of copeptin
allowed 58% of patients with non-diagnostic ECG to be ruled
out for an AMI. The availability of copeptin at baseline
reduced the time to decision for AMI diagnosis from an aver-
age of 3–1.8 h (43% reduction). Moreover, the combination of
a negative troponin and negative copeptin value on presenta-
tion allows the rule out of AMI with a negative predictive
value (NPV) > 99% [13].
Table 2 Correlation between copeptin and troponin in 6 h.
Copeptin Troponin in 6 h r-value P-value Signiﬁcance
Number of patients
+ve ve
+ve (>15.6 pg/ml) 7 25 0.212 0.180 NS
ve 0 8
Table 3 Sensitivity & Speciﬁcity of copeptin with troponin in 6 h.
Copeptin Troponin 6 h Sensitivity Speciﬁcity PPV NPV
Number of patients
+ve ve
+ve (>15.6 pg/ml) 7 25 100% 24.2% 21.2% 100%
ve 0 8
PPV, positive predictive value; NPV, negative predictive value.
Table 4 Correlation between copeptin and troponin after 12 h.
Copeptin Troponin after 12 h r-value P-value
Number of patients
+ve ve
+ve (>15.6 pg/ml) 31 1 1 0.001
ve 1 7
Table 5 Sensitivity & speciﬁcity of copeptin with troponin in 12 h.
Copeptin Troponin 12 h Sensitivity Speciﬁcity PPV NPV
Number of patients
+ve ve
+ve (>15.6 pg/ml) 31 1 96.8% 87.5% 96.8% 87.5%
ve 1 7
PPV, positive predictive value; NPV, negative predictive value.
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that combining troponin and copeptin on presentation can rule
out cases of AMI with NPV 100%.
Reichlin and Mu¨ller et al. reported the role of copeptin in
the management of 487 patients with chest pain presenting
to the emergency department (ED). This study described that
in patients who were diagnosed as having acute MI, the copep-
tin levels were elevated 0–4 h after the onset of symptoms while
troponin T was still undetectable in many patients [14].
Our study shows a strong correlation between serum copep-
tin and troponin-I measured in 12 h (P= 0.001) while there
was a poor correlation between serum copeptin and
troponin-I in ﬁrst 6 h (P= 0.18). This indicates that copeptin
is increased early in the ﬁrst 6 h before troponin has beenincreased, and both were high within 12 h from the
presentation.
Our results are supported by many studies such as the study
by Gu et al. who reported that cardiac troponin-T (cTnT) is
raised within 6–9 h from the onset of symptoms with a sensitiv-
ity of 39–43% when the patient is admitted to the ED in the
early three hours of onset. The addition of another biomarker,
such as copeptin, to cTnT may be more informative in reﬂect-
ing myocardial ischemia [15].
Reichlin et al. measured cTnT, myocardial band of creatine
kinase (CKMB), myoglobin and copeptin at the time of pre-
sentation, 3, 6 and 9 h later. They reported that plasma copep-
tin was higher than that of cTnT at the time of admission for
patients with AMI. The cTnT level was below the detection
Figure 1 The receiver operator characteristic (ROC) curve of
copeptin.
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Early ruling out of AMI at the presentation time was achieved
by combining the results of copeptin assay of 614.0 pmol/L
and cTnT assay of 60.01 lg/L with 98.8% sensitivity, 77.1%
speciﬁcity, 99.7% NPV and 46.2% positive predictive value
(PPV). Hence, the added value of copeptin to cTnT assay
accelerated clinical decision for ruling out of non-AMI
patients without the need for serial blood sampling for repeat-
ing cTnT measurement and prolonged monitoring time [14].
Our study showed high sensitivity (100%) of copeptin with
troponin measured in ﬁrst 6 h and high NPV of copeptin with
troponin-I measured in 6 h (100%). This ﬁnding may help in
early ruling out of patients with AMI who presented in the ﬁrst
six hours from the onset of chest pain.
This in agreement with Bohyn et al. who tested a rule-out
strategy using copeptin, high-sensitive troponin T, and the
Global Registry of Acute Coronary Events (GRACE) score.
They reported a NPV of 99% (95% conﬁdence interval 94–
100%) [16]. However the GRACE score was not included in
our study and we measured troponin I.
In another study by Chenvier-Gobeaux et al., the cohort
was divided into three pre-test-probability groups (low, med-
ium, or high), as assessed by the treating ED physician after
the ﬁrst clinical evaluation but before the availability of the
biomarker results. The NPVs of combined copeptin and cTnITable 6 ROC for copeptin as a predictor for myocardial infarction
AUC CI Cut-oﬀ Sensitivit
98% 0.94–1.0 21.1 pg/ml 100%
AUC, area under the curve.for diagnosis of MI were 100% (78–100) in high-risk patients,
98% (87–100)% in medium-risk patients, and 100 (95–100) in
low-risk patients [17].
Another study by Ray et al., who investigated 451 patients
with a previous history of CAD and negative cTn on admis-
sion, evaluated the additional value of copeptin to conven-
tional cTn for a rapid ruling out of AMI in patients with
acute chest pain and a previous history of CAD. In ED triage
of patients with acute chest pain suggestive of a non–ST-
segment elevation AMI and a previous history of CAD, the
combination of copeptin and cTnI allowed the clinicians to
rule out AMI on presentation, with a NPV of 98% [18].
In our study, the ROC curve was calculated for copeptin as
a predictor for myocardial infarction. The AUC for copeptin
to predict was 98% (CI = 0.94–1.0). The optimal cut-off value
of copeptin to predict was 21.1 pg/ml with a sensitivity of
100% and speciﬁcity of 87.1%, and the overall accuracy was
93.5% with a P value of 0.001.
Keller et al. evaluated different potential cut-off values for
copeptin in a large reference population (n= 1386), where the
99th percentile cutoff value was 18.9 pmol/l, the 97.5th per-
centile value was 13 pmol/l, and the 95th percentile value
was 9.8 pmol/l. Most clinical studies used a copeptin cut-off
of 14 pmol/l. This cutoff was driven by the ﬁrst copeptin assay
available and is still used in most studies. The lower the cutoff
value, the higher is the NPV for the diagnosis of AMI. To min-
imize the number of false-negative patients, a 95th percentile
value (10 pmol/l) might be advisable [11].
Piyanuttapull studied 150 patients with chest pain pre-
sented to the ED. He found that plasma copeptin level
increased and correlated with troponin-T in the diagnosis of
myocardial infarction (r= 0.317) at presentation. It further
increased and correlated (r= 0.562) at six hours after presen-
tation. Plasma copeptin levels for diagnosis of ST elevation
myocardial infarction (STEMI) at presentation have an
AUC of 0.91, sensitivity 90.9%, and speciﬁcity 87.8% with a
p value < 0.001 [19].
Our study was on conventional troponin I, which in com-
parison with the conventional troponin T, has no signiﬁcant
difference. Wu et al. who described that TnT and TnI have
similar release kinetics from the damaged myocardium. Both
troponins increase in serum within 4–9 h after AMI, peak at
12–24 h, and remain elevated for up to 14 days [20]. The differ-
ence can be signiﬁcant if high-sensitive troponin T was used in
the study instead of the conventional troponin T.
5. Limitations
Due to our limited resources, the sample size was small. The
number of patients should be increased in a multi-center basis
study..
y Speciﬁcity Accuracy P-value
87.1% 93.5% 0.001
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1. Combined measurements of troponin I and copeptin on
admission early (within 6 h) after onset of chest pain pro-
vide a high NPV for acute MI. This combination might
aid in early and safe rule-out of AMI.
2. Plasma copeptin cut-off level of 21.1 pg/ml might be used
for early rule-in of myocardial infarction to be accurately
diagnosed later by troponin measurement.
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